Receptos turns down GBP 4.1bn offer from AstraZeneca; Gilead, Teva eye rival bids
Receptos, the San Diego, California-headquartered drugs group, is believed to have turned down an approach from UK-based pharmaco AstraZeneca, The Independent reported. The market report, which cited unnamed sources, said London-listed AstraZeneca was offering USD 200 per share, or GBP 4.1bn (USD 6.3bn).
Nasdaq-quoted Receptos is believed to be waiting for a bid of USD 350 per share or more, the item reported. It noted that the company’s current stock price is USD 157.
The report went on to say that Nasdaq-listed Gilead Sciences of California and Israel-based Teva Pharmaceuticals are also hoping to acquire Receptos.
AstraZeneca declined to comment, the report said.
Independent